business / news / / NDTV Profit
Torrent Pharma's Q4 FY26 consolidated results came in ahead of the brokerage's estimates.
Nirmal Bang maintains a Hold rating on Torrent Pharmaceuticals with a target price of Rs 4,898.
KEY POINTS
- Torrent Pharma's Q4 FY26 consolidated results exceeded estimates due to JB Pharma consolidation from January 2026.
- Excluding JB Pharma, Torrent achieved 16% YoY revenue growth and sustained Ebitda margin of 32.7%.
- Early success in semaglutide launches contributed to the India business outperforming the Indian Pharma Market.
COMPANIES
Summarized by Newsio from NDTV Profit. How we summarize →